Titan Pharmaceuticals Inc. is a step closer to filing a new drug application (NDA) for its Probuphine as a weapon to fight opioid dependence. Topline results reported July 11 showed the subcutaneous implant formulation of buprenorphine met the primary end-point of a Phase III confirmatory trial. It also demonstrated noninferiority to Suboxone (buprenorphine/naloxone), a sublingual formulation and current gold standard for treating opioid addiction. South San Francisco-based Titan expects to have full results from the study by early August. After meeting with the FDA this fall, the company plans to file its NDA early next year, noted Katherine Beebe, Titan's executive vice president and …
No comments:
Post a Comment